Target intelligence / Profile preview

Albumin-bound and water-soluble uremic toxins

Molecular classification
Metabolite, Small molecule, Other
01

Overview

Albumin-bound and water-soluble toxins represent a broad category of metabolic waste products that accumulate in the blood due to impaired renal or hepatic excretory functions. Water-soluble toxins, such as urea and creatinine, are small molecules that are typically cleared efficiently by conventional hemodialysis (Vanholder et al., 2003, PMID: 12853718). In contrast, albumin-bound toxins, including indoxyl sulfate and p-cresyl sulfate, are characterized by high affinity for serum albumin, which limits their removal via standard dialysis membranes and leads to systemic accumulation (Duranton et al., 2012, PMID: 22677554). These toxins are not traditional drug targets like receptors or enzymes; rather, they are pathological substrates whose removal is the primary goal of renal replacement therapies and certain oral adsorbents. High levels of these substances are strongly associated with the progression of chronic kidney disease (CKD), cardiovascular complications, and uremic syndrome (Lin et al., 2011, PMID: 21734084). Pharmacological interventions like AST-120 (Kremezin) aim to sequester these toxins in the gastrointestinal tract to prevent their absorption into the bloodstream (Schulman et al., 2015, PMID: 25341981). In liver failure, albumin-bound toxins like bilirubin and bile acids contribute to hepatic encephalopathy and systemic organ dysfunction (Stange, 2014, PMID: 25231724).

Other names
Uremic toxinsProtein-bound uremic toxins (PBUTs)Water-soluble uremic solutesMetabolic waste productsLiver failure toxins
02

Mechanism of action

Removal from systemic circulation via extracorporeal clearance (dialysis/adsorption) or intestinal sequestration to prevent systemic accumulation (Vanholder et al., 2003, PMID: 12853718).

03

Biological functions

Metabolic waste productOsmotic solute
04

Disease associations

Chronic kidney diseaseEnd-stage renal diseaseUremiaAcute liver failureHepatic encephalopathy
05

Safety considerations

Inadequate clearance of protein-bound fractionsNon-specific removal of beneficial medicationsElectrolyte and nutrient depletion during dialysisGastrointestinal side effects of oral adsorbents
06

Interacting drugs

AST-120

3 more in the full profile.

07

Biomarkers

Serum Indoxyl Sulfatep-Cresyl SulfateBlood Urea Nitrogen (BUN)Serum CreatinineBilirubin

Beyond the preview

Go deeper on Albumin-bound and water-soluble uremic toxins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albumin-bound and water-soluble uremic toxins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call